
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Simufilam continued to demonstrate an overall favorable safety profile
Cassava's Alzheimer's disease development program with simufilam will be completely discontinued by the end of Q2 2025
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, 'Cassava', the 'Company'), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous system disorders, including Alzheimer's disease (AD) dementia and tuberous sclerosis complex (TSC)-related epilepsy, today shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD.
Topline data indicate that REFOCUS-ALZ did not meet each of the prespecified co-primary, secondary and exploratory biomarker endpoints. The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 76, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo. REFOCUS-ALZ enrolled 1,125 patients and was discontinued on November 25, 2024, following the report that a prior 52-week Phase 3 study, RETHINK-ALZ, did not meet its co-primary endpoints. A large portion of subjects enrolled in REFOCUS-ALZ completed their final study visit prior to the termination of the trial. Simufilam continued to demonstrate an overall favorable safety profile.
'We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer's disease. These results were unambiguous. Working with patients, their families and their caregivers has brought a special dignity to our Phase 3 Alzheimer's disease clinical trial program and to each of us at Cassava. We are deeply grateful for the dedication and committed efforts of study investigators and site teams, who enabled us to conduct these trials with integrity and scientific rigor and whose efforts provided a clear data read out,' said Rick Barry, President and Chief Executive Officer of Cassava.
'Cassava will discontinue all efforts to develop simufilam for Alzheimer's disease and we expect to phase out the program by the end of Q2 2025,' continued Mr. Barry. 'We remain dedicated to our mission of developing novel medicines for central nervous system disorders. While we have initiated preclinical studies to evaluate simufilam's potential as a treatment for TSC-related epilepsy, we maintain ongoing strategic expense management efforts.'
Eric Schoen, Chief Financial Officer of Cassava commented, 'We remain focused on the interests of Cassava shareholders and are committed to enhancing shareholder value. Cassava is well-capitalized with approximately $128.6 million in cash and cash equivalents as of December 31, 2024.'
Summary Study Results:
Primary Endpoint Data
Co-Primary Endpoints
LS means change from baseline to the end of the double-blind treatment period
N=372 N=376 N=372
ADAS-COG12 (±SE) 4.97 (± 0.46) 4.70 (± 0.46) 0.27 (± 0.63) P=0.67
5.26 (± 0.46) 4.70 (± 0.46) 0.56 (± 0.63) P=0.37
N=373 N=376 N=373
ADCS-ADL (±SE) - 6.27 (± 0.57) - 5.32 (± 0.57) - 0.95 (± 0.79) P=0.23
- 6.43 (± 0.57) - 5.32 (± 0.57) - 1.10 (± 0.79) P=0.16
*Based on the intent-to-treat population
BID = twice daily
ADAS-COG12 = The Alzheimer's Disease Assessment Scale – Cognitive Subscale (a lower number represents less cognitive impairment)
ADCS-ADL = Alzheimer's Disease Cooperative Study – Activities of Daily Living (a higher number represents less functional impairment)
Safety Data:
The table below provides a high-level summary of the patient demographic and safety data. Simufilam continued to demonstrate an overall favorable safety profile.
Metrics for Simufilam and Placebo Simufilam 100 mg BID Simufilam 50 mg BID Placebo BID
Baseline*
N=374 N=376 N=375
Age, mean (SD), in years 73.6 ± 8.2 74.5 ± 7.6 73.7 ± 7.9
Sex, n (%) female 208 (55.6%) 207 (55.1%) 214 (57.1%)
MMSE Score (No.%,)
21-27 240 (64.2%) 242 (64.4%) 235 (62.7%)
16-20 134 (35.8%) 134 (35.6%) 138 (36.8%)
Race/Ethnicity
White 326 (87.2%) 326 (86.7%) 313 (83.5%)
Black 17 (4.5%) 23 (6.1%) 21 (5.6%)
Asian 28 (7.5%) 21 (5.6%) 32 (8.5%)
Other 3 (0.8%) 6 (1.6%) 9 (2.4%)
Safety**
N=374 N=376 N=373
Any Adverse Event (AE) 286 (76.5%) 288 (76.6%) 282 (75.6%)
Serious AEs 43 (11.5%) 61 (16.2%) 45 (12.1%)
Death 2 (0.5%) 6 (1.6%) 3 (0.8%)
AEs leading to discontinuation from the study 32 (8.6%) 34 (9.0%) 17 (4.6%)
Most Frequent AEs ≥ 5.0%
1: COVID-19 45 (12.0%) 49 (13.0%) 40 (10.7%)
2: Urinary Tract Infection 32 (8.6%) 41 (10.9%) 34 (9.1%)
3: Fall 32 (8.6%) 43 (11.4%) 51 (13.7%)
4: Dizziness 26 (7.0%) 11 (2.9%) 23 (6.2%)
5: Diarrhea 14 (3.7%) 19 (5.1%) 15 (4.0%)
*Based on the intent-to-treat population
**Based on the safety population
BID = twice daily
AD = Alzheimer's disease
MMSE = Mini-Mental State Examination
About REFOCUS-ALZ
REFOCUS-ALZ (NCT05026177) is a Phase 3 trial designed as a multi-center, double-blinded, placebo-controlled, randomized parallel group study to evaluate the safety and efficacy of two doses of simufilam compared to a placebo in a study involving over 75 clinical trial sites in the U.S., Canada, Puerto Rico and South Korea. The clinical trial sites that conducted REFOCUS-ALZ were completely distinct from the clinical trial sites that conducted RETHINK-ALZ. REFOCUS-ALZ randomized approximately 1,125 people utilizing the same eligibility criteria as RETHINK-ALZ. Subjects were randomized 1:1:1 to receive simufilam, dosed in 50 mg or 100 mg tablets, or a matched placebo, dosed orally twice daily (BID) for 76 weeks. On November 25, 2024, the Company announced plans to discontinue the REFOCUS-ALZ study and its intention to report topline data from that trial, including the complete 52-week dataset and a large portion of 76-week data.
The prespecified co-primary endpoints for this study included the change in cognition and function from baseline to the end of the double-blind treatment period at week 76, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing each dose of simufilam to placebo. Secondary endpoints included several well validated measures of neuropsychiatric symptoms and caregiver burden. Safety was evaluated by adverse event monitoring, as well as standard laboratory and ECG assessments. The study also included an evaluation of changes in plasma and cerebrospinal fluid biomarkers from baseline to week 76, including P-tau217 (phosphorylated tau at threonine 217), GFAP (glial fibrillary acidic protein) and NFL (neurofilament light chain), as well as an evaluation of various brain volumes using MRI (magnetic resonance imaging) and amyloid and tau deposition using PET (positron emission tomography) scans from baseline to week 76.
About Simufilam
Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related epilepsy. Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein. The Company is based in Austin, Texas.
For More Information Contact:
Investors
Sandya von der Weid
Media
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
Cautionary Note Regarding Forward-Looking Statements:
This news release contains forward-looking statements that include but are not limited to statements regarding: REFOCUS-ALZ and RETHINK-ALZ, the timing for discontinuation of our Alzheimer's disease development program, our plans for the development of investigational treatments for central nervous system disorders, our plans to conduct preclinical studies of simufilam relating to seizures in TSC, the potential for simufilam as a treatment for TSC-related epilepsy, our strategic expense management efforts and the timing of anticipated milestones. These statements may be identified by words such as 'anticipate', 'before', 'believe', 'could', 'expect', 'forecast', 'intend', 'may', 'pending', 'plan', 'possible', 'potential', 'prepares for', 'will', and other words and terms of similar meaning.
Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to efficiently discontinue the Company's Alzheimer's disease development program, the ability to advance preclinical studies related to TSC-related epilepsy, and other risks inherent in drug discovery and development or specific to Cassava Sciences, Inc., as described in the section entitled 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at www.sec.gov.
All of our pharmaceutical assets under development are investigational product candidates. They have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.
Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
We are in the business of new drug discovery, development and commercialization. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery, development and commercialization, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Analyst Says Advanced Micro Devices (AMD) Can Get $25 Billion in GPU Sales With Just 5% Market Share
Advanced Micro Devices Inc (NASDAQ:AMD) is one of the 10 Stocks to Buy and Sell in 2025: Top Analyst Calls. Ben Reitzes, Melius Research managing director, recently said in a program on CNBC that Nvidia getting the permission to start selling AI chips in China is also 'great' for Advanced Micro Devices Inc (NASDAQ:AMD). He believes AMD could benefit if it manages to get even 5% of the total market share amid a rise in inference. 'Our thesis on Advanced Micro Devices Inc (NASDAQ:AMD) is I mean how could they—Lisa Su is real. She's great. She's very compelling. Nothing against Jensen, but how do they not get like 5% share of the market? Not even 10. If they get 5% of the market in 2028, that's 25 billion in GPU sales. That's like 950, 10 bucks in earnings. So, our bet on Advanced Micro Devices Inc (NASDAQ:AMD) is they have a good product. It's really good for inferencing and people are going to give them a look. So, we're hearing, you know, like Meta's a little more interested in some of the new stuff. X, XAI, OpenAI really interested. So our thesis there now, China for them is it could be like add 20% plus to their AI revenue, but they don't have—they just have one, the old chip they were selling. We need to hear about more chips to get more confident, but it's great for Advanced Micro Devices Inc (NASDAQ:AMD). Don't get me wrong. It's great for AMD.' Photo by Vishnu Mohanan on Unsplash Advanced Micro Devices (NASDAQ:AMD) bulls believe the market should stop comparing the company's chips with Nvidia and focus on its data-center growth and its competitive edge over other players like Intel. Advanced Micro Devices (NASDAQ:AMD)'s strong growth in the data center segment is indeed impressive, driven by Instinct GPU shipments and strong sales of EPYC CPUs. Advanced Micro Devices (NASDAQ:AMD) will continue to benefit from organic growth catalysts in this segment despite the competition from Nvidia. According to Goldman Sachs Research, global data center demand could surge by 160% by 2030. In the U.S., data centers are projected to use 8% of total power by 2030, up from 3% in 2022. McKinsey estimates that adding the required U.S. capacity will need over $500 billion in infrastructure investment by the decade's end. Longriver Partners Fund stated the following regarding Advanced Micro Devices, Inc. (NASDAQ:AMD) in its second quarter 2025 investor letter:
Yahoo
25 minutes ago
- Yahoo
Where Will Robinhood Markets Stock Be in 5 Years?
Key Points Robinhood's assets under management (AUM) have grown a stunning 70% in the last 12 months. Management is focused on innovation, which could lead to new revenue streams for the company. 10 stocks we like better than Robinhood Markets › Five years from now, I believe Robinhood Markets (NASDAQ: HOOD) stock will be higher than it is today. Granted, that's a vague prediction, but it's also one I feel pretty confident in. After all, while trying to pinpoint future stock prices is often a useless exercise, identifying long-term trends is far easier. So, what are these long-term trends, and why do they give me such confidence that Robinhood stock will rise over the next five years? Let's dig in and explore them one by one. Robinhood's growth engine First off, to get a grasp of where Robinhood stock might be five years from now, it's important to understand its current state of affairs. The company operates an online brokerage offering customers the ability to trade stocks, options, futures, crypto, and other financial instruments. However, it does not generate most of its revenue through traditional commissions. Instead, the company creates revenue in two main ways: First, it routes customer orders to various market makers, which pay Robinhood. This process is called payment-for-order-flow (PFOF). Second, the company generates net-interest revenue from the cash held in its customers' brokerage accounts. Currently, Robinhood has over $221 billion in assets under management (AUM). Growth of its AUM will drive higher PFOF revenue and net-interest revenue. What's more, Robinhood's AUM is growing at an incredible rate. For example, over the last year, the company's total AUM has grown from $130 billion to $221 billion, an increase of 70%. Robinhood's management Thanks to its business model and its surging popularity, Robinhood is growing rapidly. But, in my opinion, it's the company's management that will propel its stock higher over the next five years. Robinhood is led by co-founder and CEO Vlad Tenev, a 38-year-old Bulgarian-American with a penchant for thinking big. He has announced several innovative endeavors at Robinhood: Artificial intelligence (AI): Integrating AI into investing with the launch of Cortex, Robinhood's AI system. Tokenization: This could provide access for those seeking to monetize (and trade) everything from art to mortgages to private equity shares. Prediction markets: Robinhood has already launched some prediction contracts, allowing users to place bets on real-world outcomes, ranging from politics to economic data. In short, Tanev isn't satisfied with simply running another online brokerage. He wants to push the boundaries of what is possible and expand into other areas adjacent to the traditional brokerage segment. Where will Robinhood stock be in five years? While no one can say for sure where Robinhood stock will be in 2030, I do think the stock will rise from its current level. As of this writing, Robinhood has a market capitalization of around $100 billion. That makes it around the 100th-largest company in America -- roughly the same size as Intel. By 2030, I think RobinHood could move up in that ranking, perhaps challenging one of its rivals, Charles Schwab, which has a market cap of around $175 billion, making it about the 50th-largest American company. In any event, I think Robinhood's robust growth and visionary leadership make it a stock to consider right now. Should you invest $1,000 in Robinhood Markets right now? Before you buy stock in Robinhood Markets, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Robinhood Markets wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $634,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,799!* Now, it's worth noting Stock Advisor's total average return is 1,037% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Charles Schwab is an advertising partner of Motley Fool Money. Jake Lerch has the following options: long January 2026 $30 calls on Robinhood Markets. The Motley Fool has positions in and recommends Intel. The Motley Fool recommends Charles Schwab and recommends the following options: short August 2025 $24 calls on Intel and short September 2025 $92.50 calls on Charles Schwab. The Motley Fool has a disclosure policy. Where Will Robinhood Markets Stock Be in 5 Years? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Tractor Supply's New Stores Fuel Strong Sales, Solid Outlook
Tractor Supply Company (NASDAQ:TSCO) shares are trading higher Thursday after the rural lifestyle retailer reported second-quarter earnings per share of 81 cents, aligning with analyst estimates. The company also beat revenue expectations, driven by new store openings and an increase in comparable store sales, and reaffirmed its full-year 2025 financial outlook. The company reported quarterly sales of $4.44 billion (+4.5% year over year) outpacing the Street view of $4.398 billion. Comparable store sales increased 1.5% year over year, while the firm saw comparable average transaction growth of 1%.Comparable store sales growth was driven by continued momentum in year-round categories, especially consumable, usable, and edible products, and solid demand for spring seasonal items. Performance was also positive in apparel, gift and décor, as well as big ticket items. These gains were partially offset by softness in select discretionary categories. Gross profit increased 5.4% year over year to $1.64 billion. The gross margin rate was 36.9%, compared to 36.6% in the prior year's second quarter, primarily due to disciplined product cost management and the continued execution of an everyday low-price strategy. View more earnings on TSCO Operating income increased 2.9% to $577.8 million from $561.5 million in the second quarter of 2024. In the second quarter of 2025, the company opened 24 new Tractor Supply stores and two new Petsense by Tractor Supply locations. During the same period, it closed one Petsense by Tractor Supply store. 'Despite external pressures, including economic uncertainty and shifting tariffs, our year-to-date performance and visibility into the remainder of the year provide a solid foundation to reaffirm our 2025 financial outlook,' said Hal Lawton, president and chief executive officer. 'With a largely U.S.-sourced assortment, strong vendor partnerships and a flexible, scalable supply chain, we are well-positioned to navigate near-term dynamics and deliver long-term value for our shareholders.' Tractor Supply exited the quarter with cash and equivalents worth $225.81 million, with inventories worth $3.09 billion. The company's long-term debt contracted to $1.67 billion, compared with $1.73 billion in the year-ago period. Outlook Tractor Supply reaffirmed its FY2025 GAAP EPS guidance at $2.00-$2.18 per share, encompassing the $2.10 consensus estimate. It also affirmed its FY2025 sales guidance of $15.478 billion to $16.074 billion versus the $15.587 billion estimate. Price Action: TSCO shares are trading higher by 4.41% to $62.25 at last check Thursday. Read Next:Photo by refrina via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? TRACTOR SUPPLY (TSCO): Free Stock Analysis Report This article Tractor Supply's New Stores Fuel Strong Sales, Solid Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data